This is a preview of subscription content, log in via an institution to check access.
Reference
Borges A, et al. The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data. Health Economics Review : 13 Sep 2021. Available from: URL: https://doi.org/10.1186/s13561-021-00332-0
Rights and permissions
About this article
Cite this article
Neoadjuvant pertuzumab a costly addition for treating HER2+ breast cancer in Portugal. PharmacoEcon Outcomes News 887, 18 (2021). https://doi.org/10.1007/s40274-021-08034-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08034-1